Inflammasomes in cancer: a double-edged sword

Kolb, Ryan; Liu, Guanghui; Janowski, Ann M.; Sutterwala, Fayyaz S.; Zhang, Weizhou

doi:10.1007/s13238-013-3051-8

Cited by 38 publications

(56 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 Additionally, although IFI16-induced inflammasome promote the anti-virus immunity, the effects of inflammasome on many types of cancers remain controversy, including gastric cancer, colon cancer and melanoma and seem to be tissue specific. 16,17 In this study, we here found that IFI16 was down-regulated in HCC and restored its expression of IFI16 in tumour cells could increase p53dependent tumour inhibition. Moreover, IFI16-induced inflammasome was found to inhibit HCC growth and metastasis.…”

supporting

confidence: 56%

IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome

Lin

Zhao

et al. 2017

Cell Proliferation

View full text Add to dashboard Cite

show abstract

supporting

confidence: 56%

IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome

Lin

Zhao

et al. 2017

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…20 In the current study, γ-PGA showed antiinflammasome activity, which increases its potential as a promising target for cancer therapy and metabolic diseases. 13,14 Indeed, treatments targeting IL-1β (IL-1 receptor antagonist or IL-1β monoclonal antibodies), caspase-1 inhibitors or inflammasome inhibitors have been shown to control inflammasome-mediated diseases. 15,30 However, these diseases require continuous treatment because their symptoms manifest slowly, which furthers the physical and economic burden for patients.…”

Section: Discussionmentioning

confidence: 99%

“…13 Collectively, inflammasomes have received increased attention as new therapeutic targets of tumors and metabolic disorders. 14,15 In this study, we investigated the effects of γ-PGA on inflammasome activation. γ-PGA attenuated IL-1β and IL-18 secretion, which are readouts of inflammasome activation, in the presence of NLRP3, NLRC4 and AIM2 triggers.…”

Section: Introductionmentioning

confidence: 99%

Poly-gamma-glutamic acid from Bacillus subtilis upregulates pro-inflammatory cytokines while inhibiting NLRP3, NLRC4 and AIM2 inflammasome activation

et al. 2016

View full text Add to dashboard Cite

Poly-gamma-glutamic acid (γ-PGA) is a natural, edible and non-toxic polymer synthesized by Bacillus subtilis and is suggested as a safe biomaterial for the use in hydrogels and vaccine adjuvants. However, the effect of γ-PGA on inflammasome activation has not yet been studied in macrophages. Inflammasomes, which are intracellular multi-protein complexes, promote acute and chronic inflammation via interleukin-1β or interleukin-18 maturation, and they are known targets for metabolic syndromes and cancer. In this study, we observed that γ-PGA attenuated NLRP3, NLRC4 and AIM2 inflammasome activation, whereas it upregulated pro-inflammatory cytokine expression in human and murine macrophages. Although γ-PGA had conflicting effects on cytokine production and maturation, it clearly alleviated the severity of lipopolysaccharide-induced endotoxin shock in an animal model. Thus, we suggest γ-PGA as a candidate to control inflammasome-mediated disorders.

show abstract

“…However, excessive or inappropriate activation of NLRP3 inflammasome is implicated in the pathogenesis of inherited and acquired inflammatory diseases, leading to increased inflammatory responses in lung metastases and suppression of antitumor immunity in certain conditions . The NLRP3 inflammasome also plays an important role in the development and progression of gastrointestinal cancer, skin cancer, breast cancer and hepatocellular carcinoma . Furthermore, the over‐expressed and constitutively activated NLRP3 inflammasome contributes to the progression of late‐stage melanoma, whereas it is considerably down‐regulated in human hepatocellular carcinoma …”

Section: Nlrp3 Inflammasome and Tumorigenesismentioning

confidence: 99%

Differential role of the NLRP3 inflammasome in infection and tumorigenesis

Tartey

Kanneganti

2019

Immunology

View full text Add to dashboard Cite

Dysregulated inflammation is one of the hallmarks of cancer initiation and progression. Emerging evidence indicates that inflammasomes play a central role in regulating immune cell functions in various infections and cancer. Inflammasomes are multimeric complexes consisting of nucleotide-binding oligomerization domain (NOD) -like receptors (NLRs). Among the NLRs, NOD1, NOD2 and NLRP3 respond to a variety of endogenous (i.e. damage-associated molecular patterns) and exogenous (i.e. pathogen-associated molecular patterns) stimuli. The NLRP3 inflammasome is associated with the onset and progression of autoinflammatory and autoimmune diseases, including metabolic disorders, multiple sclerosis, inflammatory bowel disease, and cryopyrin-associated periodic fever syndrome. NLRP3 is also associated with a wide variety of infections and tumorigenesis that are closely correlated with chemotherapy response and prognosis. In this review, we explore the rapidly expanding body of research on the expression and functions of NLRP3 in infections and cancers and outline novel inhibitors targeting the NLRP3 inflammasome that could be developed as therapeutic alternatives to current anticancer treatment.

show abstract

Inflammasomes in cancer: a double-edged sword

Cited by 38 publications

References 90 publications

IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome

IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome

Poly-gamma-glutamic acid from Bacillus subtilis upregulates pro-inflammatory cytokines while inhibiting NLRP3, NLRC4 and AIM2 inflammasome activation

Differential role of the NLRP3 inflammasome in infection and tumorigenesis

Contact Info

Product

Resources

About